Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054481 | 0.91 | ATM (0.45) | SCN9AAAK1CTSSCTSKATM | |
| SCHEMBL6875991 | 0.85 | SIRT5 (0.40) | SCN9AAAK1CTSSCTSKATM | |
| SCHEMBL6874637 | 0.84 | SCN9A (0.45) | SCN9AAAK1CTSSCTSKATM | |
| SCHEMBL10054498 | 0.84 | SCN9A (0.45) | SCN9AAAK1CTSSCTSKATM | |
| SCHEMBL10078090 | 0.83 | SCN9A (0.38) | SCN9AAAK1CTSSCTSKATM | |
| SCHEMBL10054496 | 0.82 | ATM (0.44) | SCN9AAAK1CTSSCTSKATM | |
| SCHEMBL10054503 | 0.82 | SCN9A (0.43) | SCN9AAAK1CTSSCTSKATM | |
| SCHEMBL10054499 | 0.81 | SCN9A (0.45) | SCN9AAAK1CTSSCTSKATM | |
| SCHEMBL12849500 | 0.81 | SCN9A (0.45) | SCN9AAAK1CTSSCTSKATM | |
| SCHEMBL10054507 | 0.81 | SCN9A (0.45) | SCN9AAAK1CTSSCTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | SERPINB1, CMA1, CPA3 | SCN9A 4524/4885AAK1 3587/4885CTSS 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.